| Literature DB >> 26145251 |
Suzana Boltes Cecatto1, Matilde Monteiro-Soares2, Teresa Henriques2, Eurico Monteiro3, Carla Isabel Ferreira Pinto Moura4.
Abstract
INTRODUCTION: Pharyngocutaneous fistula after larynx and hypopharynx cancer surgery can cause several damages. This study's aim was to derive a clinical decision rule to predict pharyngocutaneous fistula development after pharyngolaryngeal cancer surgery.Entities:
Keywords: Complicações pós-operatórias; Deiscência da ferida operatória; ENT surgical procedures; Fístula das glândulas salivares; Laringectomia; Laryngeal neoplasms; Laryngectomy; Neoplasias laríngeas; Postoperative complications; Procedimentos cirúrgicos otorrinolaringológicos; Salivary gland fistula; Surgical wound dehiscence
Mesh:
Year: 2015 PMID: 26145251 PMCID: PMC9442709 DOI: 10.1016/j.bjorl.2014.09.009
Source DB: PubMed Journal: Braz J Otorhinolaryngol ISSN: 1808-8686
American Society of Anesthesiologists risk classification system.
| ASA class | Class definition |
|---|---|
| I | Normal healthy patient |
| II | Patient with mild systemic disease |
| III | Patient with systemic disease that is not incapacitating |
| IV | Patient with an incapacitating systemic disease that is a constant threat to life |
| V | A moribund patient who is not expected to survive for 24 hours with or without operation |
Characterization of the sample according to TNM stage (AJCC Cancer Staging Manual, 2010 – 7th edition) and demographic features.
| Characteristic | Frequency | % |
|---|---|---|
| Demographic features | ||
| Male gender | 166 | 97.1 |
| Age (>60 years) | 75 | 43.9 |
| Smoking habits (>20 cigarettes/day) | 142 | 83 |
| Stage | ||
| I | 1 | 0.6 |
| II | 5 | 2.9 |
| III | 38 | 22.2 |
| IVa | 120 | 70.2 |
| IVb | 7 | 4.1 |
| T | ||
| Tis | 1 | 0.6 |
| T1 | 1 | 0.6 |
| T2 | 5 | 2.9 |
| T3 | 45 | 26.3 |
| T4a | 119 | 69.6 |
| N | ||
| N0 | 83 | 48.5 |
| N1 | 25 | 14.6 |
| N2a | 28 | 16.4 |
| N2b | 17 | 9.9 |
| N2c | 13 | 7.6 |
| N3 | 5 | 2.9 |
Univariate and multivariate analysis of the relationship between the variables included in the clinical decision rule and the frequency of pharyngocutaneous fistula.
| Variables | All | With fistula | Without fistula | Univariate analysis | Multivariate analysis |
|---|---|---|---|---|---|
| ASA | |||||
| 2 | 107 (63) | 25 (51.1) | 82 (68) | 0.05 | 0.005 |
| 3 | 62 (36.2) | 23 (48.9) | 39 (32) | ||
| Alcohol | |||||
| Heavy | 126 (73.7) | 38 (79.2) | 88 (71.5) | 0.34 | 0.361 |
| Hemoglobin pre | |||||
| <12.4 g/dL | 65 (39.6) | 22 (48.9) | 43 (36.1) | 0.15 | 0.665 |
| Albumin pre | |||||
| <37.0 g/L | 30 (34.1) | 7 (25) | 23 (38.3) | 0.24 | 0.07 |
| Co morbidities | |||||
| DM | 25 (14.6) | 8 (16.7) | 17 (13.8) | 0.63 | 0.72 |
| COPD | 18 (10.5) | 3 (6.2) | 15 (12.2) | 0.4 | |
| Liver disease | 39 (22.8) | 11 (22.9) | 28 (22.8) | 1 | |
| Cardiopathy | 42 (24.6) | 11 (22.9) | 31 (25.2) | 0.85 | |
| N | |||||
| N0 | 83 (48.6) | 21 (43.8) | 62 (50.4) | 0.25 | 0.933 |
| N1 | 25 (14.6) | 8 (16.7) | 17 (13.8) | ||
| N2a + N2b + N2c | 58 (33.9) | 17 (9.94) | 41 (23.96) | ||
| N3 | 5 (2.9) | 2 (1.16) | 3 (1.74) | ||
| Location | |||||
| Larynx | 67 (39.2) | 18 (10.5) | 49 (28.6) | 0.86 | 0.539 |
| Pharyngolaryngeal | 104 (60.8) | 30 (62.5) | 74 (60.2) | ||
| Rt pre | |||||
| Yes | 12 (7.0) | 4 (8.3) | 8 (6.5) | 0.74 | |
| CRT pre | |||||
| Yes | 15 (8.8) | 9 (18.8) | 6 (4.9) | 0.01 | 0.120 |
| Tracheotomy pre | |||||
| Yes | 77 (45) | 28 (58.3) | 49 (39.8) | 0.04 | 0.144 |
Rt, radiotherapy; CRT, chemoradiotherapy; pre, preoperative; DM, diabetes mellitus; COPD, chronic obstructive pulmonary diseases.
Fisher's exact test.
Chi-squared test.
Figure 1Model's area under the receiver operating characteristic curve. Ivory line, line of reference of AUC 0.5; blue line, score of the model; green line, four categories of the model.
Risk stratification of developing fistula pharyngocutaneous for the model.
| Pharyngocutaneous fistula | Risk groups | Total | |||
|---|---|---|---|---|---|
| Low risk | Medium-low risk | Medium-high risk | High risk | ||
| No | 17 (89%) | 16 (80%) | 22 (73%) | 4 (24%) | 59 |
| Yes | 2 (11%) | 4 (20%) | 8 (27%) | 13 (76%) | 27 |
| 19 | 20 | 30 | 17 | 86 | |
Risk stratification of modelCat2 and validity measures for the different cut-offs.
| Cut-off | Fistulas | Se % | Spec % | LR+ | LR− | PPV % | PNV % |
|---|---|---|---|---|---|---|---|
| High risk (4) | 13 (48) | 48 (29–67) | 93 (86–99) | 7.10 (2.5–19.7) | 0.55 (0.38–0.80) | 76 (56–96) | 79 (70–89) |
| Medium-high (3) + high risk (4) | 21 (77) | 77 (62–93) | 55 (43–68) | 1.76 (1.2–2.5) | 0.39 (0.18–0.83) | 44 (30–58) | 84 (73–95) |
| Medium-low (2) + medium-high (3) + high risk (4) | 25 (92) | 92 (82–102) | 28 (17–40) | 1.30 (1.0–1.5) | 0.25 (0.06–1.03) | 37 (25–48) | 89 (75–103) |
Se, sensibility; Spec, specificity; LR+, positive likelihood; LR−, negative likelihood; PPV, positive predictive value; PNV, negative predictive value; 95% CI, 95% confidence interval.
Risk stratification of the American Society of Anesthesiologists classification and precision measurements.
| ASA | Fistula | Se % | Spec % | LR+ | LR− | PPV % | NPV % |
|---|---|---|---|---|---|---|---|
| ASA 3 | 23 (48.9) | 47 (33–62) | 67 (59–76) | 1.48 (1–2.2) | 0.76 (0.57–.03) | 37 (25–49) | 76 (68–84) |
Se, sensitivity; Spec, specificity; LR+, positive likelihood; LR−, negative likelihood; PPV, positive predictive value; NPV, negative predictive value; 95% CI, 95% confidence interval.